- Nanjing InxMed announced a $15 million B+ funding round to develop its novel therapies that target the stroma microenvironment and drug resistance for hard-to-treat solid tumors. InxMed will use the funds for US/China clinical trials of its lead drug, IN10018.
- US-based Coherus Biosciences returned the US rights to market an Innovent Avastin biosimilar to Innovent, blaming the COVID-19 epidemic for slowing its development of the biosimilar.
- Ascletis Pharma of Hangzhou was approved to start US trials of its in-licensed PD-L1 as an immune restoration/functional cure of AIDS (HIV-1).
For further details see:
Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops